Skip to main content
NCBI home page
Infection and Immunity logoLink to Infection and Immunity
. 1987 Nov;55(11):2706–2714. doi: 10.1128/iai.55.11.2706-2714.1987

Serological relationships between Escherichia coli and Salmonella smooth- and rough-mutant lipopolysaccharides as revealed by enzyme-linked immunosorbent assay for human immunoglobulin G antiendotoxin antibodies.

G R Barclay 1, B B Scott 1
PMCID: PMC259965  PMID: 3312008

Abstract

Reactions of sera from healthy blood donors to smooth and rough mutant lipopolysaccharides (LPS) from Escherichia coli O111:B4 and Salmonella minnesota which had been complexed with polymyxin B were determined by enzyme-linked immunosorbent assay. Relative enzyme-linked immunosorbent assay reactivities were examined for prima facie evidence of cross-reactivity by analyses of correlation and relative scatter. Patterns of reactivity were interpreted in relation to published structures. Evidence was obtained for two dominant epitopes associated with the lipid A-2-keto-3-deoxyoctulosonic acid and heptose regions of the LPS core. Sera demonstrated apparent exclusive antibody homogeneity in that given sera showed only one of the two possible specificities, which occurred with equal frequency. Cross-reactivity was found in the lipid A-2-keto-3-deoxyoctulosonic acid region for all LPS. Cross-reactivity was found in the heptose region for larger rough mutant S. minnesota LPS and smooth S. minnesota LPS and for E. coli O111:B4 LPS but not for E. coli rough mutant J5 LPS, whose heptose region appears to be different from those of the other organisms.

Full text

PDF
2706

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Baumgartner J. D., Glauser M. P., McCutchan J. A., Ziegler E. J., van Melle G., Klauber M. R., Vogt M., Muehlen E., Luethy R., Chiolero R. Prevention of gram-negative shock and death in surgical patients by antibody to endotoxin core glycolipid. Lancet. 1985 Jul 13;2(8446):59–63. doi: 10.1016/s0140-6736(85)90176-x. [DOI] [PubMed] [Google Scholar]
  2. Brade H., Rietschel E. T. Alpha-2----4-interlinked 3-deoxy-D-manno-octulosonic acid disaccharide. A common constituent of enterobacterial lipopolysaccharides. Eur J Biochem. 1984 Dec 3;145(2):231–236. doi: 10.1111/j.1432-1033.1984.tb08543.x. [DOI] [PubMed] [Google Scholar]
  3. Cohen J. Anti-endotoxin immunotherapy in septic shock. J Antimicrob Chemother. 1986 Oct;18(4):436–439. doi: 10.1093/jac/18.4.436. [DOI] [PubMed] [Google Scholar]
  4. DuPont H. L., Spink W. W. Infections due to gram-negative organisms: an analysis of 860 patients with bacteremia at the University of Minnesota Medical Center, 1958-1966. Medicine (Baltimore) 1969 Jul;48(4):307–332. doi: 10.1097/00005792-196907000-00003. [DOI] [PubMed] [Google Scholar]
  5. ELBEIN A. D., HEATH E. C. THE BIOSYNTHESIS OF CELL WALL LIPOPOLYSACCHARIDE IN ESCHERICHIA COLI. I. THE BIOCHEMICAL PROPERTIES OF A URIDINE DIPHOSPHATE GALACTOSE 4-EPIMERASELESS MUTANT. J Biol Chem. 1965 May;240:1919–1925. [PubMed] [Google Scholar]
  6. Freeman R., Gould F. K. Prevention of fever and gram negative infection after open heart surgery by antiendotoxin. Thorax. 1985 Nov;40(11):846–848. doi: 10.1136/thx.40.11.846. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Fuller N. A., Wu M., Wilkinson R. G., Heath E. C. The biosynthesis of cell wall lipopolysaccharide in Escherichia coli. VII. Characterization of heterogeneous "core" oligosaccharide structures. J Biol Chem. 1973 Nov 25;248(22):7938–7950. [PubMed] [Google Scholar]
  8. Jansson P. E., Lindberg A. A., Lindberg B., Wollin R. Structural studies on the hexose region of the core in lipopolysaccharides from Enterobacteriaceae. Eur J Biochem. 1981 Apr;115(3):571–577. doi: 10.1111/j.1432-1033.1981.tb06241.x. [DOI] [PubMed] [Google Scholar]
  9. Jones R. J., Roe E. A., Gupta J. L. Controlled trial of Pseudomonas immunoglobulin and vaccine in burn patients. Lancet. 1980 Dec 13;2(8207):1263–1265. doi: 10.1016/s0140-6736(80)92334-x. [DOI] [PubMed] [Google Scholar]
  10. Kreger B. E., Craven D. E., Carling P. C., McCabe W. R. Gram-negative bacteremia. III. Reassessment of etiology, epidemiology and ecology in 612 patients. Am J Med. 1980 Mar;68(3):332–343. doi: 10.1016/0002-9343(80)90101-1. [DOI] [PubMed] [Google Scholar]
  11. Lachman E., Pitsoe S. B., Gaffin S. L. Anti-lipopolysaccharide immunotherapy in management of septic shock of obstetric and gynaecological origin. Lancet. 1984 May 5;1(8384):981–983. doi: 10.1016/s0140-6736(84)92324-9. [DOI] [PubMed] [Google Scholar]
  12. Law B. J., Marks M. I. Age-related prevalence of human serum IgG and IgM antibody to the core glycolipid of Escherichia coli strain J5, as measured by ELISA. J Infect Dis. 1985 Jun;151(6):988–994. doi: 10.1093/infdis/151.6.988. [DOI] [PubMed] [Google Scholar]
  13. Marget W., Mar P. J., Jaspers L., Possinger K., Haslberger H. Preliminary study on administration of high-titer lipid A antibody serum in sepsis and septic shock patients. Infection. 1985 May-Jun;13(3):120–124. doi: 10.1007/BF01642870. [DOI] [PubMed] [Google Scholar]
  14. McCabe W. R., Kreger B. E., Johns M. Type-specific and cross-reactive antibodies in gram-negative bacteremia. N Engl J Med. 1972 Aug 10;287(6):261–267. doi: 10.1056/NEJM197208102870601. [DOI] [PubMed] [Google Scholar]
  15. McClelland D. B., Yap P. L. Clinical use of immunoglobulins. Clin Haematol. 1984 Feb;13(1):39–74. [PubMed] [Google Scholar]
  16. Morrison D. C., Jacobs D. M. Binding of polymyxin B to the lipid A portion of bacterial lipopolysaccharides. Immunochemistry. 1976 Oct;13(10):813–818. doi: 10.1016/0019-2791(76)90181-6. [DOI] [PubMed] [Google Scholar]
  17. Morrison D. C., Leive L. Fractions of lipopolysaccharide from Escherichia coli O111:B4 prepared by two extraction procedures. J Biol Chem. 1975 Apr 25;250(8):2911–2919. [PubMed] [Google Scholar]
  18. Peterson A. A., Hancock R. E., McGroarty E. J. Binding of polycationic antibiotics and polyamines to lipopolysaccharides of Pseudomonas aeruginosa. J Bacteriol. 1985 Dec;164(3):1256–1261. doi: 10.1128/jb.164.3.1256-1261.1985. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Schindler M., Osborn M. J. Interaction of divalent cations and polymyxin B with lipopolysaccharide. Biochemistry. 1979 Oct 2;18(20):4425–4430. doi: 10.1021/bi00587a024. [DOI] [PubMed] [Google Scholar]
  20. Schmidt G., Fromme I., Mayer H. Immunochemical studies on core lipopolysaccharides of Enterobacteriaceae of different genera. Eur J Biochem. 1970 Jun;14(2):357–366. doi: 10.1111/j.1432-1033.1970.tb00297.x. [DOI] [PubMed] [Google Scholar]
  21. Scott B. B., Barclay G. R. Endotoxin-polymyxin complexes in an improved enzyme-linked immunosorbent assay for IgG antibodies in blood donor sera to gram-negative endotoxin core glycolipids. Vox Sang. 1987;52(4):272–280. doi: 10.1111/j.1423-0410.1987.tb04893.x. [DOI] [PubMed] [Google Scholar]
  22. Stein R., Heath E. C. Incorporation of N-acetylglucosamine into the core region of the cell wall lipopolysaccharide of Escherichia coli. J Biol Chem. 1979 May 25;254(10):4101–4109. [PubMed] [Google Scholar]
  23. Trautmann M., Hahn H. Antiserum against Escherichia coli J5: a re-evaluation of its in vitro and in vivo activity against heterologous gram-negative bacteria. Infection. 1985 May-Jun;13(3):140–145. doi: 10.1007/BF01642875. [DOI] [PubMed] [Google Scholar]
  24. Westphal O., Jann K., Himmelspach K. Chemistry and immunochemistry of bacterial lipopolysaccharides as cell wall antigens and endotoxins. Prog Allergy. 1983;33:9–39. [PubMed] [Google Scholar]
  25. Young L. S. Symposium on infectious complications of neoplastic disease (Part II). Immunoprophylaxis and serotherapy of bacterial infections. Am J Med. 1984 Apr;76(4):664–671. doi: 10.1016/0002-9343(84)90292-4. [DOI] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES